Scribd Logo
Upload

Welcome to Scribd!

  • 10 Protein Cancer Biomarkers

    Uploaded by

    rd timola
    9 views1 page
    The FDA approved 10 protein cancer biomarkers. These include alpha-fetoprotein and carcinoembryonic antigen for liver and colon cancers, CA 125 for ovarian cancer, thyroglobulin for thyroid cancer, PSA for prostate cancer, and CA 15-3, CA 27-29, HER2/neu for breast cancer monitoring and diagnosis. Each biomarker is associated with specific cancer types and can help clinicians differentiate between benign and malignant conditions or monitor cancer recurrence.

    Original Description:

    Protein Cancer Biomarkers

    Original Title

    10-PROTEIN-CANCER-BIOMARKERS

    Copyright

    © © All Rights Reserved

    Available Formats

    PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    Report this Document
    The FDA approved 10 protein cancer biomarkers. These include alpha-fetoprotein and carcinoembryonic antigen for liver and colon cancers, CA 125 for ovarian cancer, thyroglobulin for thyroid cancer, PSA for prostate cancer, and CA 15-3, CA 27-29, HER2/neu for breast cancer monitoring and diagnosis. Each biomarker is associated with specific cancer types and can help clinicians differentiate between benign and malignant conditions or monitor cancer recurrence.

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd
    Flag for inappropriate content
    9 views1 page

    10 Protein Cancer Biomarkers

    Uploaded by

    rd timola
    The FDA approved 10 protein cancer biomarkers. These include alpha-fetoprotein and carcinoembryonic antigen for liver and colon cancers, CA 125 for ovarian cancer, thyroglobulin for thyroid cancer, PSA for prostate cancer, and CA 15-3, CA 27-29, HER2/neu for breast cancer monitoring and diagnosis. Each biomarker is associated with specific cancer types and can help clinicians differentiate between benign and malignant conditions or monitor cancer recurrence.

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd
    Flag for inappropriate content
    of 1

    The Food and Drug Administration (FDA)

    approved 10 protein cancer biomarkers.

    Alpha-Fetoprotein Carcinoembryonic Antigen


    ● Found in: Fetal Liver/Yolk Sac ● Found in: Fetal Endocrine Tissue
    ● Normally secreted in: Serum - In the 2nd Trimester of
    ● Nanograms (ng) or Milligrams Gestation
    (mg) in quantities ● Valuable in: Differentiating
    benign and malignant pleural
    CA 125 and ascitic effusion
    ● Mucin-like glycoprotein ● Found in patients with: Colon
    ● Valuable in: Ovarian and Cancer, Lung Cancer, Breast
    Endometrial Carcinomas Cancer, Liver Cancer,
    ● Expressed in the surfaces of: Pancreatic Cancer
    Coelomic Epithelium and Human
    Ovarian Carcinoma Cells CA 19-9
    ● More sensitive in: Low-Stage ● Also known as Gastrointestinal
    Ovarian Cancer Cancer-Associated Antigen
    ● Mainly used for: Colorectal and
    Thyroglobulin Pancreatic Carcinoma biomarkers
    ● Produced and used by: Thyroid ● It’s a glycolipid
    Gland ● Greater specificity for
    ● Monitors CA recurrence Pancreatic Cancer than
    ● Increased (↑) in: Thyroid Carcinoembryonic Antigen
    Cancer, Grave’s disease,
    Thyroiditis CA 15-3
    ● Main purpose: To monitor
    Prostate Specific Antigen (PSA) Mastectomy patients and
    ● Produced by: Prostatic Epithelial Metastasis
    Cells ● High Level: >32 U/mL -
    ● The serum of the PSA is directly Advanced Breast Cancer and
    proportional to the tumor large tumor burden
    volume
    ● Elevated in: Prostate infection, CA 27-29
    Irritation, BPH, Recent ejaculation ● Breast Carcinoma-Associated
    Antigen
    Prostatic Acid Phosphatase ● Predicts the early recurrence of
    ● Older marker for: Prostate Breast Cancer
    Cancer ● Not recommended as Breast
    ● Serum enzyme that is Cancer Screening Assay
    exclusively used to diagnose
    Prostatic Carcinomas HER2/neu
    ● Overexpressed in 15% to 20%
    of invasive Breast Cancer
    ● Tumor aggressiveness, Reduced
    survival rate
    ● Predictive assay for tumor
    susceptibility to Lapatinib and
    Trastuzumab therapy

    You might also like